{
  "id": 14741214,
  "title": "Schizophrenia and type 2 diabetes are linked, but GLP-1s could help manage the risks",
  "url": "https://urgent.news/2026/10/15/schizophrenia-and-type-2-diabetes-are-linked-but-glp-1s-could-help",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-15T16:20:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-schizophrenia-diabetes-linked-glp-1s.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric hospitalization and psychiatric emergency department visits in people with both schizophrenia and type 2 diabetes (T2D), compared with no GLP-1 treatment or treatment with newer diabetes medications, according to new research published in The Lancet Psychiatry.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}